Studio Investment Management LLC grew its stake in Danaher Co. (NYSE:DHR – Free Report) by 4.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,449 shares of the conglomerate’s stock after purchasing an additional 59 shares during the period. Studio Investment Management LLC’s holdings in Danaher were worth $403,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the stock. Allen Capital Group LLC raised its holdings in Danaher by 24.3% during the third quarter. Allen Capital Group LLC now owns 1,519 shares of the conglomerate’s stock worth $422,000 after purchasing an additional 297 shares in the last quarter. AlphaCore Capital LLC increased its position in Danaher by 18.9% during the 3rd quarter. AlphaCore Capital LLC now owns 3,895 shares of the conglomerate’s stock worth $1,084,000 after purchasing an additional 619 shares during the period. Darden Wealth Group Inc purchased a new position in shares of Danaher during the 3rd quarter worth approximately $217,000. 49 Wealth Management LLC acquired a new stake in shares of Danaher in the 3rd quarter valued at approximately $259,000. Finally, Lathrop Investment Management Corp boosted its stake in shares of Danaher by 13.8% in the third quarter. Lathrop Investment Management Corp now owns 25,705 shares of the conglomerate’s stock valued at $7,147,000 after buying an additional 3,125 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Transactions at Danaher
In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 18.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 11.10% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Research Report on DHR
Danaher Stock Performance
Shares of NYSE DHR opened at $235.83 on Friday. The company has a 50-day simple moving average of $258.15 and a 200-day simple moving average of $259.88. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market cap of $170.33 billion, a PE ratio of 45.01, a price-to-earnings-growth ratio of 4.25 and a beta of 0.85. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the company earned $2.02 EPS. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, equities analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Tesla Investors Continue to Profit From the Trump Trade
- Following Congress Stock Trades
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.